METASTATIC BREAST CANCER

This early-phase study tests a vaccine called PVX-410, alone or with the immunotherapy drug pembrolizumab, in 20 women with metastatic triple negative breast cancer who have a specific genetic marker (HLA-A2+). The goal is to see if the vaccine safely boosts the immune system to …

This study tests three drug combinations for people with a common type of advanced breast cancer (ER+/HER2-). The goal is to see if adding palbociclib or both palbociclib and avelumab to fulvestrant can help control the cancer longer. About 220 participants who have already recei…

This study looks at whether people with HER2-positive metastatic breast cancer who have done very well on anti-HER2 therapy (cancer controlled for 3+ years) can safely stop that treatment. Researchers will monitor those who stop versus those who continue to see if the cancer stay…

This study tests whether giving denosumab every 12 weeks instead of every 4 weeks is just as effective at preventing bone complications (like fractures or spinal cord compression) in people with metastatic breast or prostate cancer. About 1,380 participants will be followed to co…

This study tests a new oral drug called elacestrant in 61 people with a common type of advanced breast cancer (ER+/HER2-). Participants have not received a specific class of targeted therapy (CDK4/6 inhibitors) before. The main goal is to see how long the drug can control cancer …

This study tests a drug called Trastuzumab-Deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors and tumors elsewhere in the body. Participants receive the drug intravenously, and doctors m…

This study looks at whether adding a high-dose, precise type of radiation called SBRT to usual treatments (like hormone therapy or chemo) can delay cancer progression in people with 1 to 5 bone metastases from breast, lung, or prostate cancer. About 168 adults aged 18-75 with goo…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and a targeted drug can help people with a certain type of advanced breast cancer (ER+/HER2-). The trial includes 57 participants whose cancer did not respond well to initial treatment. …

This study tests a drug called olaparib in people with metastatic breast cancer that has spread beyond the breast. Participants must have a specific genetic change in their tumor that may make it sensitive to this drug. The goal is to see if olaparib can shrink tumors or slow can…

This study offers continued access to the drug ribociclib for people with metastatic breast cancer who are already taking it and seeing benefits in a previous Novartis study. The main goal is to monitor long-term safety and side effects. About 134 participants will be followed wh…

This study tests if a very low-carb (ketogenic) diet, a low-carb diet, or the diabetes drug canagliflozin can prevent high blood sugar caused by the cancer drug alpelisib. The goal is to see if controlling blood sugar helps alpelisib work better for people with metastatic PIK3CA-…

This study was designed to see if the drug trastuzumab deruxtecan works better than standard CDK4/6 inhibitors for people with a specific type of advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was planned for adults with metastatic disease. However, the trial w…

This study compares a new drug, RPH-051, to an existing drug called Perjeta for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. Both drugs are given together with trastuzumab and docetaxel as the first treatment. The main goal is to see if…

This study tests a new drug called onvansertib combined with standard chemotherapy (paclitaxel) in people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating to see if the combination is safe and c…

This study compares a new drug, sacituzumab govitecan, to standard chemotherapy in people with a common type of advanced breast cancer (HR+/HER2-) that has not responded to at least two prior chemotherapies. The goal is to see if the new drug can slow cancer growth or improve sur…

This study tests a new drug called DB-1303 against standard chemotherapy in about 541 people with a specific type of advanced breast cancer (HER2-low, HR-positive) that has stopped responding to hormone therapy. The main goal is to see if DB-1303 can delay cancer growth better th…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study looks at whether continuing the drug palbociclib but switching to a different hormone therapy (fulvestrant) can help people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to palbociclib and an aromatase inhibitor.…

This study tests a combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. About 46 women with advanced …

This study tests a combination of specially trained immune cells (HER2 BATs) and the drug pembrolizumab in women with metastatic breast cancer that has spread. The goal is to find a safe dose and see if the treatment can shrink tumors. About 22 women will take part, receiving up …

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people with HER2-positive breast cancer that has spread. The goal is to find safe doses and see if the combination shrinks tumors. About 245 adults with advanced or metastatic di…

This phase 3 study tests whether a combination of two oral targeted drugs (fluorizoparib and apatinib) can keep a specific type of advanced breast cancer from growing longer than standard chemotherapy. The trial includes 200 women with HRD-positive, HER2-negative breast cancer. A…

This study tests a drug called abemaciclib, given alone or with tamoxifen, in women with a certain type of advanced breast cancer (HR+, HER2-) that has not responded to previous treatments. The goal is to see if these treatments can slow cancer growth or shrink tumors. About 234 …

This early-stage trial tests a radioactive drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug targets cancer cells that have a protein called SSTR on their surface. The study aims to find t…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a certain type of advanced breast cancer (HR+/HER2-) live longer without the disease getting worse. About 110 participants will receive either the drug alone or the combination. Th…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people whose breast cancer has spread and has low levels of a protein called HER2. The main goals are to see if the combinations are safe and to find the best doses. About 138 ad…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) in people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. The trial includes 14 adults whose…

This study looks at whether a 9-month structured and personalized exercise program can reduce cancer-related physical fatigue and improve quality of life in 357 people with stage IV (metastatic) breast cancer. Participants will follow an exercise plan tailored to their abilities …

This study tracks 65 people with metastatic breast cancer to see if a blood test for Circulating Tumor Cells (CTCs) helps doctors choose and monitor treatments. Participants give blood samples, and doctors answer surveys about how useful the CTC results are. The goal is to learn …

This study looks at how the drug tucatinib enters and works in brain tumors from HER2+ cancers (like breast, lung, and stomach cancers). Researchers will compare genetic differences between tumors that have stopped responding to tucatinib and those being treated for the first tim…

This study looks at whether a simple blood test that tracks cancer DNA (ctDNA) can help doctors decide when to switch treatments for people with stage IV breast cancer. The goal is to see if changing therapy earlier, based on the blood test, can keep the cancer under control long…

This study looks at how much time people with advanced breast or ovarian cancer spend on cancer-related tasks like appointments, travel, medications, and paperwork. About 78 participants will use a smartphone app for 28 days to track their activities and complete daily surveys. T…

This study uses a special PET scan called FLT PET/CT to look at how active breast cancer tumors are before and during treatment with two drugs (ribociclib and paclitaxel). About 20 adults with metastatic breast cancer that has spread beyond the liver and bones will take part. The…

This study looks back at medical records of nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. The goal is to understand how these patients are treated in everyday practice and how long they live. No new treatments are tested; instead, researcher…

This study looks at whether eating only during certain hours of the day (time-restricted eating) can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty means losing strength and independence. The study will test if this eating pattern h…